Premium
Parasympathetic vasoactive intestinal peptide ( VIP ): a likely contributor to clozapine‐induced sialorrhoea
Author(s) -
Ekström J,
Godoy T,
Loy F,
Riva A
Publication year - 2014
Publication title -
oral diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.953
H-Index - 87
eISSN - 1601-0825
pISSN - 1354-523X
DOI - 10.1111/odi.12139
Subject(s) - vasoactive intestinal peptide , saliva , endocrinology , clozapine , medicine , submandibular gland , salivary gland , receptor , antagonist , schizophrenia (object oriented programming) , neuropeptide , psychiatry
Objective The parasympathetic transmitter vasoactive intestinal peptide ( VIP ) increases salivary gland blood flow and evokes protein secretion and, in some species, such as rats, a small fluid secretion. It interacts synergistically with muscarinics for protein and fluid output. Human salivary acini are supplied with VIP ‐containing nerves. We hypothesise that VIP and clozapine, acting together, evoke a volume of saliva greater than the sum of those induced by each drug given separately. It was further considered whether, in the current test situation, circulatory events influenced the magnitude of the secretory response. Material and Methods Saliva from parotid glands deprived of their autonomic innervation, and saliva and blood from innervated submandibular glands were collected in adrenoceptor antagonist‐pretreated pentobarbitone‐anaesthetised rats. Initially, the individual and then the combined effects of intravenous doses of VIP and clozapine were established. Results The submandibular volume response to the combination was 2–3 times higher, while blood pressure and glandular blood flow did not differ from those to VIP alone. The synergism occurred independent of nerves as shown in denervated parotid glands. Conclusions From the current preclinical data, we speculate that VIP of parasympathetic origin, by its synergistic interaction with clozapine, may contribute to the clozapine (muscarinic M1‐receptor)‐induced sialorrhoea in schizophrenics.